High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults

Tinna Traustadottir, Anthoney A. Stock, S. Mitchell Harman

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid-lowering agents widely employed for atherosclerosis prevention. HMG-CoA reductase blockade reduces skeletal muscle coenzyme Q 10 (CoQ10) levels and mitochondrial respiratory chain activities and may produce mild to severe skeletal muscle myopathy. This study investigated whether high-dose statin treatment would result in measurably decreased exercise capacity in older men and women. Maximal oxygen consumption, aerobic endurance, oxygen uptake kinetics, maximal strength, muscular power, and muscular endurance were measured before and after 12 weeks of statin treatment (simvastatin, 80 mg/day) in nine men and one woman, ages 55-76 years, with LDL-cholesterol levels >3.3 mmol/l (mean=4.2±0.2 mmol/l). Myalgia symptoms were assessed every 4 weeks. As expected, statin treatment resulted in significant decreases in LDL- and total-cholesterol levels (P<0.01) with no significant changes in HDL-cholesterol or triglyceride levels. No significant changes were observed in aerobic capacity, endurance, oxygen kinetics or any measures of muscle function. No subject reported symptoms of myalgia, cramps, or weakness during the study. In the absence of myalgia or myopathic symptoms, high-dose simvastatin treatment did not impair exercise capacity in hyperlipidemic older individuals. We conclude that decreases in intramuscular CoQ10, in most patients on high dose statin treatment may not be clinically relevant, due to inter-individual variability in the degree of CoQ10 depletion, sensitivity of muscle to decreases in CoQ 10, or both.

Original languageEnglish (US)
Pages (from-to)283-291
Number of pages9
JournalAge
Volume30
Issue number4
DOIs
StatePublished - Dec 2008
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Skeletal Muscle
Ubiquinone
Myalgia
coenzyme Q10
Simvastatin
LDL Cholesterol
Oxidoreductases
Exercise
Oxygen
Therapeutics
Muscle Cramp
Muscles
Muscular Diseases
Electron Transport
Oxygen Consumption
HDL Cholesterol
Atherosclerosis
Triglycerides
Lipids

Keywords

  • Aging
  • Myalgia
  • O2 uptake kinetics
  • Simvastatin
  • Strength
  • Vo2max

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. / Traustadottir, Tinna; Stock, Anthoney A.; Harman, S. Mitchell.

In: Age, Vol. 30, No. 4, 12.2008, p. 283-291.

Research output: Contribution to journalArticle

Traustadottir, Tinna ; Stock, Anthoney A. ; Harman, S. Mitchell. / High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. In: Age. 2008 ; Vol. 30, No. 4. pp. 283-291.
@article{c8cb3316a5be492ba978f0321a947b8c,
title = "High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults",
abstract = "3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid-lowering agents widely employed for atherosclerosis prevention. HMG-CoA reductase blockade reduces skeletal muscle coenzyme Q 10 (CoQ10) levels and mitochondrial respiratory chain activities and may produce mild to severe skeletal muscle myopathy. This study investigated whether high-dose statin treatment would result in measurably decreased exercise capacity in older men and women. Maximal oxygen consumption, aerobic endurance, oxygen uptake kinetics, maximal strength, muscular power, and muscular endurance were measured before and after 12 weeks of statin treatment (simvastatin, 80 mg/day) in nine men and one woman, ages 55-76 years, with LDL-cholesterol levels >3.3 mmol/l (mean=4.2±0.2 mmol/l). Myalgia symptoms were assessed every 4 weeks. As expected, statin treatment resulted in significant decreases in LDL- and total-cholesterol levels (P<0.01) with no significant changes in HDL-cholesterol or triglyceride levels. No significant changes were observed in aerobic capacity, endurance, oxygen kinetics or any measures of muscle function. No subject reported symptoms of myalgia, cramps, or weakness during the study. In the absence of myalgia or myopathic symptoms, high-dose simvastatin treatment did not impair exercise capacity in hyperlipidemic older individuals. We conclude that decreases in intramuscular CoQ10, in most patients on high dose statin treatment may not be clinically relevant, due to inter-individual variability in the degree of CoQ10 depletion, sensitivity of muscle to decreases in CoQ 10, or both.",
keywords = "Aging, Myalgia, O2 uptake kinetics, Simvastatin, Strength, Vo2max",
author = "Tinna Traustadottir and Stock, {Anthoney A.} and Harman, {S. Mitchell}",
year = "2008",
month = "12",
doi = "10.1007/s11357-008-9070-3",
language = "English (US)",
volume = "30",
pages = "283--291",
journal = "GeroScience",
issn = "2509-2715",
publisher = "Springer International Publishing AG",
number = "4",

}

TY - JOUR

T1 - High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults

AU - Traustadottir, Tinna

AU - Stock, Anthoney A.

AU - Harman, S. Mitchell

PY - 2008/12

Y1 - 2008/12

N2 - 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid-lowering agents widely employed for atherosclerosis prevention. HMG-CoA reductase blockade reduces skeletal muscle coenzyme Q 10 (CoQ10) levels and mitochondrial respiratory chain activities and may produce mild to severe skeletal muscle myopathy. This study investigated whether high-dose statin treatment would result in measurably decreased exercise capacity in older men and women. Maximal oxygen consumption, aerobic endurance, oxygen uptake kinetics, maximal strength, muscular power, and muscular endurance were measured before and after 12 weeks of statin treatment (simvastatin, 80 mg/day) in nine men and one woman, ages 55-76 years, with LDL-cholesterol levels >3.3 mmol/l (mean=4.2±0.2 mmol/l). Myalgia symptoms were assessed every 4 weeks. As expected, statin treatment resulted in significant decreases in LDL- and total-cholesterol levels (P<0.01) with no significant changes in HDL-cholesterol or triglyceride levels. No significant changes were observed in aerobic capacity, endurance, oxygen kinetics or any measures of muscle function. No subject reported symptoms of myalgia, cramps, or weakness during the study. In the absence of myalgia or myopathic symptoms, high-dose simvastatin treatment did not impair exercise capacity in hyperlipidemic older individuals. We conclude that decreases in intramuscular CoQ10, in most patients on high dose statin treatment may not be clinically relevant, due to inter-individual variability in the degree of CoQ10 depletion, sensitivity of muscle to decreases in CoQ 10, or both.

AB - 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid-lowering agents widely employed for atherosclerosis prevention. HMG-CoA reductase blockade reduces skeletal muscle coenzyme Q 10 (CoQ10) levels and mitochondrial respiratory chain activities and may produce mild to severe skeletal muscle myopathy. This study investigated whether high-dose statin treatment would result in measurably decreased exercise capacity in older men and women. Maximal oxygen consumption, aerobic endurance, oxygen uptake kinetics, maximal strength, muscular power, and muscular endurance were measured before and after 12 weeks of statin treatment (simvastatin, 80 mg/day) in nine men and one woman, ages 55-76 years, with LDL-cholesterol levels >3.3 mmol/l (mean=4.2±0.2 mmol/l). Myalgia symptoms were assessed every 4 weeks. As expected, statin treatment resulted in significant decreases in LDL- and total-cholesterol levels (P<0.01) with no significant changes in HDL-cholesterol or triglyceride levels. No significant changes were observed in aerobic capacity, endurance, oxygen kinetics or any measures of muscle function. No subject reported symptoms of myalgia, cramps, or weakness during the study. In the absence of myalgia or myopathic symptoms, high-dose simvastatin treatment did not impair exercise capacity in hyperlipidemic older individuals. We conclude that decreases in intramuscular CoQ10, in most patients on high dose statin treatment may not be clinically relevant, due to inter-individual variability in the degree of CoQ10 depletion, sensitivity of muscle to decreases in CoQ 10, or both.

KW - Aging

KW - Myalgia

KW - O2 uptake kinetics

KW - Simvastatin

KW - Strength

KW - Vo2max

UR - http://www.scopus.com/inward/record.url?scp=56749164925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749164925&partnerID=8YFLogxK

U2 - 10.1007/s11357-008-9070-3

DO - 10.1007/s11357-008-9070-3

M3 - Article

VL - 30

SP - 283

EP - 291

JO - GeroScience

JF - GeroScience

SN - 2509-2715

IS - 4

ER -